In China, teachers have shy students choose papers to help them socialize; if a paper is blank, the class doesn't do the homework.
Since all the papers are blank, the child always wins.
They are called “Indie” dogs.
As if they are ordinary.
As if they are less.
But Indie dogs are among the strongest, most resilient, and intelligent breeds you will ever meet.
They survive extreme heat, heavy rains, traffic, hunger, and neglect. Their immunity is naturally stronger. They adapt better. They are fiercely loyal. Once they trust you, they love you for life.
And yet, they are the most abandoned.
Hit by vehicles.
Chased away.
Starved.
Ignored while foreign breeds get chosen first.
An Indie puppy doesn’t need luxury.
Just safety.
Just food.
Just someone who won’t leave.
Adoption doesn’t just give them a home it gives them dignity. It breaks the cycle of suffering. It turns a street survivor into a family member.
If you are thinking of bringing a dog home, choose compassion over fashion.
Adopt an Indie.
You won’t just change their life.
They will change yours forever.
#adoptDontShop#Dogs
New in #practicalRO: Understanding Patient Priorities for Religious and Spiritual Needs During Radiation Therapy for Gynecological Malignancies. This paper was presented at Poster Q&A Session 02 at #ASTRO25. tinyurl.com/amjacobs1
Remembering Acharya P.C. Ray — scientist, reformer, entrepreneur.
His pursuit of indigenous science, social equity & industrial self-reliance continues to guide today's Bharat.
An inspiration to every scientist, policymaker & changemaker shaping an #AtmanirbharBharat.
Very low prevalence of HPV ve oropharyngeal cancers in India. To be precise only 11%. Our paper one of the large single institution studies with 630 patients highlights the differences in outcomes & need to focus on treatment intensification strategies
10.1038/s44276-025-00164-z
From cobalt in 1959 to proton therapy in 2023, our journey @RadOncTMC has been one of service, training, & innovation.
Proud to stand strong this @WorldRTDay, shaping cancer care across India & beyond as we advocate for timely, equitable access to RT
#OneVoiceForRadiotherapy
🧠 Cancer responds. Surgeons wait. Patients lose.
In our new Converse Study (n=2,379 HCC patients), 16% responded well enough to be potentially cured after Atezolizumab Bevacizumab.
But only 3% actually received curative treatment.
We call this the under-conversion gap:
Patients respond.
But nobody changes the plan.
Intent stays palliative. Hope fades.
🎯 Tumor down. AFP down.
Still… no resection, no ablation, no transplant.
Why?
🔹 No expert MDT
🔹 No transplant program
🔹 No mindset shift
👉 Immunotherapy changed the biology.
Now we must change the strategy.
📢 If we don’t act on response, we waste it.
🧩 Read the full study (Liver Cancer, 2025):
doi.org/10.1159/000547792#HCC#Immunotherapy#UnderConversion#LiverCancer#Oncology#Hepatology#MDT#SurgicalOncology#CHESS#ConversionTherapy#CancerCare#AIinOncology#MTH#CTH
Some ask if patients with limited metastatic disease can be cured. The answer is clearly yes.
We’ve known that since the 1930’s, and it was very clearly articulated in this book from the 1960s.
In 2026 we’ll report the final outcomes from SABR-COMET, 10 years after closure.
I followed the patient for 10 years with no recurrence before discharging him. Here's his last CT.
This reminds us that behind every KM curve, there are individual people with individual stories who agree to join our studies.
I learned this week that SABR-COMET patient #1 recently passed away, more than 12 years after enrollment, with no recurrence since his original SABR.
We initially treated him for a left adrenal met. It’s an interesting story… ⬇️⬇️⬇️
📢 Save the Dates!
Join us for the @RadOncTMC Annual Practicum 2025
🌀 Nuances of Proton Beam Therapy - From Commissioning to Clinics
📅 12–13 September 2025 (Fri–Sat)
📍 Proton Therapy Center, @ACTREC_TMC, Navi Mumbai